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1. What we need to know about β-thalassemia
Thalassemia is a hereditary, autosomal recessive blood disorder due to partial 
or complete deficiency in the synthesis of or β-globin chains (β-thalassemia) or 
α-globin chains (α-thalassemia) that compose the major adult hemoglobin resulting 
in chronic hemolytic state.
β-Thalassemia is caused by mutations in the HBB gene resulting in decrease of 
the production of β chain leading to excessive accumulation of unpaired α chains 
that aggregate and precipitates along the red cell membranes, causing their damage 
and resulting in intravascular hemolysis. Also, premature destruction of erythroid 
precursors results in intramedullary death and ineffective erythropoiesis and a 
short lifespan of mature RBCs in the circulation. Frequent RBC transfusion is the 
main supportive therapy, leading to excessive accumulation of iron (iron overload), 
a condition that is exacerbated by excessive hemolysis and the increased iron 
reabsorption secondary to ineffective erythropoiesis.
Excessive iron is toxic and catalyzes the generation of reactive oxygen species, 
which in excess are toxic, causing damage to numerous body organs such as the 
heart and liver as well as the endocrine system. Herein, we represent an overview 
on thalassemia regarding the underlying pathophysiology of the disease, clinical 
presentations, and potential therapeutic modalities for the amelioration of its 
complications, as well as new modalities that may provide a cure for the disease. 
Thanks to the significant improvement in therapy, patients with β-thalassemia may 
reach an advanced age.
1.1 β-Thalassemia: types and clinical presentation
In the homozygous state of β-thalassemia which is known as thalassemia major 
represented with severe, transfusion-dependent anemia within the first 2 years of 
life. Also associated with skeletal abnormalities and poor growth, in the hetero-
zygous state of β-thalassemia (trait or minor) causes mild to moderate microcytic 
anemia and not require any specific management. On the other hand, patients in 
whom clinical severity of the disease lies between that of thalassemia major and 
thalassemia trait are classified as having β-thalassemia intermedia and require only 
periodic blood transfusions under special circumstances [1]. Numerous different 
genotypes are associated with β-thalassemia intermedia, such as HbE which is a 
common Hb variant found in Southeast Asia, and this variant is included in the beta 
thalassemia category of diseases. Also, HbS (sickle cell disease) can be presented 
clinically with severe anemia [2].
Repeated blood transfusions resulting in excessive iron deposition and genera-
tion of ROS is a leading cause of morbidity and mortality, in those patients [3].
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1.2 Removal of excess iron
Removal of blood (phlebotomy) is used to remove excess iron in patients with 
normal Hb levels, such as in patients with hereditary hemochromatosis, where iron 
overload is caused by mutations in the iron homeostasis system [4].
Most other patients with iron overload are anemic (Hb < 10 g/dL) and, there-
fore, particularly those who are transfusion dependent, phlebotomy would not be 
optimum and will require iron chelation therapy to decrease iron overload [5].
1.3 Iron chelators
Each unit of transfused red blood cells contains approximately 200 mg of 
elemental iron. In addition to anemia and ineffective erythropoiesis down-regulates 
the synthesis of hepcidin, so the use of iron chelators is mandatory to remove excess 
iron from the plasma as well as from tissues through binding the cheatable, labile, 
iron form and enhancing its excretion through the body excreta.
Three chelation agents are approved for use in the United States. Deferoxamine, 
the first to be used, is given by continuous intravenous infusion or slow subcutane-
ous, infusion through a portable pump. Its main disadvantage is poor compliance 
secondary to its mode of administration [6].
Deferiprone is an oral iron chelator effective in removing excess iron from the 
organs and mainly from the heart. The main potential complication is neutropenia 
that may rarely be followed by agranulocytosis. A liquid formulation has been 
recently introduced [7].
Deferasirox is available as oral dispersible tablets and is considered as an effec-
tive oral chelator, and it reduces liver iron concentration and serum ferritin levels. 
Deferasirox binds iron with high affinity in a 2:1 ratio. Its main side effects are GIT 
upsets in the form of abdominal pain, nausea, diarrhea, liver, and kidney dysfunc-
tion as well as skin rash. A new formulation of film-coated tablets are now available 
with better compliance, as it can be taken with a light meal [8].
1.3.1 Shuttle mechanism
The efficacy of chelation may be improved by the use of a combination of chela-
tors. For example, deferiprone may mobilize iron from tissues into the circulation, 
where deferoxamine binds and facilitates its excretion in the urine this is what is 
called (the “shuttle mechanism”) [9].
1.4 Dyserythropoiesis
Chronic anemia in addition to associated hypoxia in β-thalassemia stimulates 
excessive RBC production which is mediated through release of erythropoietin, 
the main erythropoietic stimulating hormone. This attempt is called “stress 
erythropoiesis” that passes through four steps: expansion of erythroid progeni-
tors, accelerated erythroid differentiation, maturation arrest, and apoptosis. 
Many other factors, for example, transforming growth factor-β and activin 
receptor-II trap ligands contribute to this phenomenon. Binding of EPO to 
its surface receptor on erythroid precursors activates transduction pathways, 
including Jak2/Stat5, which inhibit apoptosis and stimulates proliferation as well 
as differentiation of the new cells. However, this operation is futile termed inef-
fective erythropoiesis due to oxidative stress-increased apoptosis and abortive 
differentiation [10].
3Introductory Chapter: β-Thalassemia
DOI: http://dx.doi.org/10.5772/intechopen.90946
Recent advances in understanding the molecular mechanism involved in two 
critical steps of dyserythropoiesis are paving the way to new alternative therapeutic 
targets.
1.5 Novel therapeutic modalities
Several therapeutic modalities aimed at reducing the dyserythropoiesis in thal-
assemia are currently under research. For example, activin receptor-II trap ligands, 
JAK2 inhibitors, induction of the Hsp70 chaperone machinery, reducing α-globin 
synthesis, and stimulation of HbF production [11–15].
1.5.1 Gene modification approach
The hematopoietic stem cells of the affected individual are subjected to gene edit-
ing techniques ex vivo and then reinjected again to the patient for reconstitution [16].
To increase the production of γ-globin lentiviral vectors that express a zinc 
finger protein has been used in order to carry microRNAs that silence its repressors 
or interacts with the promoter of the γ-globin gene 80 [17].
Genome editing of the promoter of BCL11A can be accomplished by several 
nucleases, such as engineered zinc finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs), and clustered regularly interspaced short palin-
dromic repeats linked to Cas9 nucleases (CRISPR-Cas9) (Figure 1) [18]. Recently, 
it has been shown that ZFN-driven BCL11A enhancer ablation leads to increased 
production of HbF in erythroid progenitors derived hematopoietic stem cell from 
β-thalassemia patient which could be used for autologous transplantation [19]. 
Similarly, CRISPR-Cas9-mediated BCL11A enhancer inactivation in a human adult-
stage erythroid cell line can achieve the same results [20].
Figure 1. 
Mechanism of gene editing.
Beta Thalassemia
4
1.5.2 Gene therapy
Currently, gene therapy represents a novel therapeutic promise, after many 
years of extensive preclinical research for the optimization of gene transfer 
regimen. This is mediated through autologous transplantation of genetically 
modified hematopoietic stem cells, clinical trials being held worldwide have 
revealed that, by re-establishing effective hemoglobin production, patients may 
be rendered transfusion- and chelation-independent and escapes the immu-
nological sequel that normally accompany allogeneic hematopoietic stem cell 
transplantation.
The approach of gene therapy has focused on two mechanisms: first, increasing 
the production of β-globin by the addition of a normal gene or correction of the 
mutated gene; and second, increasing the production of γ-globin by the addition 
of its gene, overexpression of its endogenous activating transcription factors, and 
silencing of its repressors. Studies of gene therapy have utilized mainly lentivirus 
vectors in experimental systems, including cultured CD34 HSCs from β-thalassemia 
patients and β-thalassemia mouse models. Yet the safety profile of such technologies 
is still uncertain [16].
Genomic editing has been demonstrated to modify the β-globin gene. 
Thus, TALEN-mediated gene correction has been used in induced HSCs from 
β-thalassemia patients [21].
1.5.3 Allogeneic hematopoietic stem cell transplantation
Currently, allogeneic stem cell transplant [allo-SCT] remains the only curative 
option for the majority of patients with β-thalassemia major before development of 
iron overload complications [22].
Patients with β-thalassemia major who have good risk features are reasonable 
to anticipate a greater than 90% chance of successful transplant outcome, even 
patients with high risk features, success rates are approaching 80%.
Challenging in allo-HSCT in high-risk patients is mainly related to graft rejec-
tion and risk of transplant-related mortality but nowadays novel modified or 
reduced-intensity conditioning regimens are used to improve the transplantation 
outcome in β-thalassemia patients with cheerful results [23].
Traditionally, completely matched human leukocyte antigen identical siblings 
have been used as donors, and on the other hand, matched unrelated donors have 
also been tried in patients with low risk. Bone marrow has been known as the 
preferred choice of stem cells in non-malignant hematological disorders to reduce 
the risk of GVHD but peripheral blood stem cell graft and cord stem cell when used 
have been reported to be associated with faster engraftment, lower requirement of 
blood product support in the peri-transplant period, and a low incidence of graft 
rejection in patients with low-risk [24, 25].
1.6 Preventive strategies for thalassemia
Despite the great advances in management tools used in β-thalassemia to 
improve the cure rate of the disease, yet the incidence rate of the disease is increas-
ing especially in underdeveloped countries where the prevalence of consanguineous 
marriage is high and low level of standard and sometimes shortage in medical 
resources and supply that limit the early detection of carrier state. Therefore, the 
prevention of the homozygous state presents a big challenging issue. Prevention 
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including prenatal diagnosis, carrier detections, molecular diagnosis, and genetic 
counseling is strongly needed.
1.6.1 Prenatal diagnosis
Recently, prenatal diagnosis is carried out for couples at risk, either in first 
trimester through obtaining fetal material by chorionic villus sampling or in the 
second trimester through cordocentesis or amniocentesis.
One of the main successful procedures in prenatal diagnosis is to study the 
fetal erythroid cells and detection of globin gene mutations. As the first primitive 
erythroblasts appear in embryonic bloodstream around the 4–5 weeks gestations, so 
obtaining fetal material by aspiration of coelomic fluid (celocentesis) followed by 
selection of embryo-fetal erythroid precursors by an anti-CD71 microbeads method 
or by direct micromanipulator pickup of the cells has been extensively improved 
and used by several groups [26, 27].
Nowadays, the possibility of cheaper and safer prenatal diagnosis facilities has 
emerged. Fetal-derived genetic material (cells or cell free DNA) can be obtained 
from the maternal blood and analyzed, which is considered a non-invasive maneu-
ver with no risk of miscarriage and needs neither complicated procedures nor 
highly trained personnel for sampling. This allows future screening for thalassemia 
as well as other genetic diseases [28].
Detection or exclusion of inherited fetal mutations is one of the most important 
approaches that focuses on detection of mutation that are absent from mother’s 
Figure 2. 
Beta-thalassemia: causes, symptoms, and therapeutic modalities. Causes and symptoms are marked in red; and 
therapeutic modalities are marked in blue.
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genome that requires DNA quantifications with high sensitivity. Even when the 
parents have the identical mutation, the relative mutation/haplotype approach 
might detect this fetal mutation [29].
1.6.2 Pre-implantation genetic diagnosis
One of the promising approaches is pre-implantation genetic diagnosis of 
cells (PGD) usually single cells, which had been biopsied from oocytes/zygotes or 
embryos obtained by in vitro fertilization and testing it for specific genetic abnor-
mality. PGD assists couples to avoid birth of an affected child and limit the needs 
for abortion. This maneuver aims at delivery of an unaffected newborn. PGD helps 
to identify unaffected embryos for transfer to the uterus [30].
Lastly to conclude, the most likely approach to reduce the patients’ load is effi-
cient prevention, carrier detection, prenatal diagnosis, and genetic counseling, and 
here, we summarize causes, symptoms, and therapeutic modalities in β-thalassemia 
as illustrated in Figure 2.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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